New Stock News | Lupine Pharmaceutical intends to list on the Hong Kong stock exchange. The China Securities Regulatory Commission requires additional explanations on offshore infrastructure construction and the compliance of return mergers and acquisitions.

According to the Wisdom Finance APP, on December 26th, the China Securities Regulatory Commission released the "Supplementary Materials Requirements for Overseas Issuance and Listing Filings (December 22, 2025 to December 26, 2025)". The International Department of the China Securities Regulatory Commission announced the supplementary material requirements for 19 companies, including the requirement for Lupin Pharmaceutical to provide further explanations on the establishment of offshore structures and the compliance of outbound mergers and acquisitions. According to the disclosure of the Hong Kong Stock Exchange on October 31st, Lupin Pharmaceutical Limited submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor.